Teva Recalls Metoprolol Tartrate Tablets Due to Weight Variations
Teva Pharmaceuticals is recalling 2,268 bottles of Metoprolol Tartrate 50 mg tablets in Ohio because some tablets may not meet weight specifications.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, but the hazard involves tablet weight variations without reported injuries or illnesses, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling 2,268 bottles of Metoprolol Tartrate Tablets USP 50 mg, 1000 count. The affected product is prescription-only and was manufactured in India by Emcure Pharmaceuticals Ltd. for Teva Pharmaceuticals USA. The specific lot number is TE1Y261, with an expiration date of 12/2013.
The recall was initiated because some tablets in this lot may not conform to weight specifications, potentially resulting in tablets that are under or over weight. The agency has classified this as a Class II recall. The affected product was distributed in Ohio.
Consumers who have this specific lot of Metoprolol Tartrate Tablets should contact their healthcare provider or pharmacist for guidance on how to proceed. Patients should not discontinue their medication without consulting a medical professional.
The recalled product
- Product
- Metoprolol Tartrate Tablets USP 50 mg, 1000 count bottle, Rx only, Manufactured in india By: Emcure Pharmaceuticals LTD. Hinjwadi, Pune, India, Manufactured for TEVA Phamaceuticals USA, Sellersville, PA 18960, NDC 0093-0733-10
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 2,268
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #TE1Y261
- Exp
- 12/2013
Distribution
Distributed in 1 state:
Related recalls
Same manufacturer · Teva Pharmaceuticals USA, Inc.
See all →- SevereTeva Recalls Trazodone Hydrochloride Tablets Due to Foreign Material
FDA (Drugs) · 2026-09-09
- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine 0.3 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · weight variation
See all →- ModerateAurobindo Recalls Amphetamine Mixed Salts Tablets for Out-of-Specification Weight
FDA (Drugs) · 2019-10-23
Similar recalls
- ModerateTeva Recalls Propranolol Hydrochloride Tablets Due to Weight Specification Failures
FDA (Drugs) · 2013-09-04
- ModerateTeva Recalls Methyldopa Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2014-05-21
- HighTeva metoprolol succinate 50 mg tablets failed dissolution specifications
FDA (Drugs) · 2026-03-11
- ModerateTeva Recalls Metoprolol Succinate Extended Release Tablets Due to Dissolution Failure
FDA (Drugs) · 2018-10-31
- ModerateTeva Recalls Ethambutol Hydrochloride Tablets Due to Incorrect Excipient
FDA (Drugs) · 2014-03-12
- ModerateTeva Recalls Indomethacin Capsules Due to Manufacturing Quality Deviations
FDA (Drugs) · 2014-05-21